Fenbendazole (FZ), a broad-spectrum benzimidazole anthelmintic, has recently garnered attention for its potential anti-cancer properties. While it is primarily utilised as a deworming agent in veterinary medicine, emerging preclinical studies and anecdotal evidence indicate that it may exhibit anti-tumor effects in specific types of cancer.
Mycogenics Fenbenzadole
R180,00
(In stock)
Fenbendazole may reduce glucose uptake in certain cancer cells, depriving them of energy and enhancing the effectiveness of treatments such as chemotherapy or radiation. Additionally, it may boost immune activity against tumours by influencing specific immune pathways, potentially improving the body’s ability to detect and attack cancer cells. Considerations: Fenbendazole is generally considered safe at normal doses but may cause mild gastrointestinal upset (nausea, diarrhea), liver enzyme elevation (rare, more common in long-term use), and potential drug interactions (especially with chemotherapy drugs).
In stock
Reviews
There are no reviews yet.